MannKind Corp. (NASDAQ:MNKD) has been given a consensus rating of “Hold” by the ten analysts that are presently covering the firm. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $2.56.

A number of equities analysts recently weighed in on MNKD shares. S&P Equity Research lowered their price objective on shares of MannKind Corp. from $0.84 to $0.70 in a research report on Wednesday, August 31st. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of MannKind Corp. in a research report on Monday, August 8th. Finally, Piper Jaffray Cos. reaffirmed an “underweight” rating on shares of MannKind Corp. in a research report on Tuesday, August 9th.

MannKind Corp. (NASDAQ:MNKD) opened at 0.5588 on Tuesday. The stock’s 50 day moving average price is $0.68 and its 200-day moving average price is $1.05. The firm’s market capitalization is $267.13 million. MannKind Corp. has a 12 month low of $0.54 and a 12 month high of $3.79.

MannKind Corp. (NASDAQ:MNKD) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.01. During the same period last year, the business posted ($0.07) EPS. Equities analysts forecast that MannKind Corp. will post ($0.23) earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in MNKD. Commonwealth Equity Services Inc increased its position in shares of MannKind Corp. by 8.7% in the second quarter. Commonwealth Equity Services Inc now owns 93,615 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 7,497 shares during the period. Commerzbank Aktiengesellschaft FI increased its position in shares of MannKind Corp. by 2.6% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 129,291 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 3,309 shares during the period. BlackRock Advisors LLC increased its position in shares of MannKind Corp. by 24.1% in the second quarter. BlackRock Advisors LLC now owns 148,155 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 28,777 shares during the period. Profund Advisors LLC increased its position in shares of MannKind Corp. by 8.9% in the second quarter. Profund Advisors LLC now owns 179,005 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 14,653 shares during the period. Finally, American International Group Inc. increased its position in shares of MannKind Corp. by 2.6% in the second quarter. American International Group Inc. now owns 186,680 shares of the biopharmaceutical company’s stock valued at $217,000 after buying an additional 4,663 shares during the period. Institutional investors and hedge funds own 18.90% of the company’s stock.

MannKind Corp. Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

5 Day Chart for NASDAQ:MNKD

Receive News & Stock Ratings for MannKind Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corp. and related stocks with our FREE daily email newsletter.